Hormonal contraception is one of birth control methods which act on the endocrine system. Several types of female hormones are used to prevent ovulation and avoid fertilization. Hormonal contraception also results in changes in the uterus making it unlikely to develop pregnancy. Hormonal contraceptives are available in a variety of forms like patch worn on the skin, pill, injection, implant in the arm, or intrauterine devices. These are safe and reliable forms of hormonal contraceptives to prevent pregnancy.
The global hormonal contraceptives market is likely to show significant growth during the forecast period. This is attributed to the urbanization, increasing user awareness, rise in menstruating population worldwide, and encouragement by government to use contraceptives.
The hormonal contraceptives market is segmented by method, by hormone, by end users and by geography. Based on method, the market is segmented into combined oral, oral, implanted, injected, intrauterine, transdermal patch, and vaginal ring contraceptives. The hormonal contraceptives market, by hormone is categorized into androgens, estrogens, progestrogens, gonadotropins, antiandrogens, and others. Based on end users, the market is segmented into hospitals, homecare, gynecology centers, clinics, and ambulatory surgical centers (ASC).
On the basis of regions, the global hormonal contraceptives market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa.
Some of the major players in the global hormonal contraceptives market Amgen (U.S.), Bayer Healthcare Pharmaceuticals (Germany), Cipla Limited (India), Glenmark Pharmaceuticals (India), Lupin Pharmaceuticals, Inc (India), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Piramal Healthcare Limited (India), Sun Pharmaceutical Industries Ltd. (India), and Teva Pharmaceutical Industries (Israel).
Table of Contents
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency & Pricing
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
220.127.116.11 Key Data From Secondary Sources
2.2.2 Primary Research
18.104.22.168 Key Data From Primary Sources
2.3 Market Size Estimation Methodology
2.4 Market Forecast Methodology
2.5 Market Data Validation and Data Triangulation
3 Executive Summary
4 Premium Insights
5 Market Overview
5.2 Market Segmentation
5.3 Market Dynamics
6 Hormonal Contraceptives Market, By Method
6.2 Combined Oral Contraceptives
6.3 Oral Contraceptives
6.4 Implanted Contraceptives
6.5 Injected Contraceptives
6.7 Trasdermal Patch
6.8 Vaginal Ring
7 Hormonal Contraceptives Market, By Hormones
8 Hormonal Contraceptivesmarket, By End-Users
8.4 Gynecology Centers
8.6 Ambulatory Surgical Centers (ASC)
9 Hormonal Contraceptives Market, By Geography
9.2 North America
9.5 Rest of the World
10 Competitive Landscape
10.2 Market Share Analysis
10.3 Competitive Situation and Trends
10.3.1 New Product Launches
10.3.3 Agreements, Partnerships, and Collborations
11 Company Profiles
(Overview, Financials, Products & Services, Strategy, & Developments)*
11.3 Bayer Healthcare Pharmaceuticals
11.4 Cipla Limited
11.5 Glenmark Pharmaceuticals
11.6 Lupin Pharmaceuticals, Inc.
11.7 Novartis AG
11.8 Pfizer, Inc.
11.9 Piramal Healthcare Limited
11.10 Sun Pharmaceutical Industries Ltd.
11.11 Teva Pharmaceutical Industries
12.1 Discussion Guide
12.2 Introducing Rt: Real-Time Market Intelligence
12.3 Available Customizations
12.4 Related Reports
1. All the Above Markets Will Be Provided for the Years 2014, 2015, 2016, and 2021
2. Revenue for Companies Listed Under “Company Profile” Section (Chapter 10) Might Not Be Captured for Companies Whose Financial Data is Not Available in Public Domain
3. The Above Scope is Tentative and is Subject to Change as the Research Progresses